Despite notable improvement in toxicity management following early mitigation strategies with anti-IL6R and steroids, CRS and ICANS, two specific side effects, are still the leading causes of acute morbidity, ICU transfer and prolonged hospitalization [10, 13]. Here, IL6R is linked to congenital rubella syndrome.